Michele Milella

List of Publications by Citations

173 papers	10,347 citations	38 h-index	100 g-index
188 ext. papers	12,131 ext. citations	5.8 avg, IF	5.47 L-index

#	Paper	IF	Citations
173	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncology, The*, **2012**, 13, 239-46	21.7	3985
172	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 1374-1385	21.7	818
171	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. *Oncotarget*, **2011**, 2, 135-64	3.3	456
170	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. *PLoS ONE*, **2015**, 10, e0130142	3.7	339
169	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. *Lancet Oncology, The*, **2018**, 19, 521-536	21.7	315
168	Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. *Cancer Research*, **2006**, 66, 5549-54	10.1	285
167	PTEN: Multiple Functions in Human Malignant Tumors. *Frontiers in Oncology*, **2015**, 5, 24	5.3	284
166	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. *Oncotarget*, **2012**, 3, 1068-111	3.3	250
165	Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. *Oncotarget*, **2012**, 3, 954-87	3.3	214
164	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial **2018**, 6, 7		191
163	The mTOR pathway: a new target in cancer therapy. *Current Cancer Drug Targets*, **2010**, 10, 484-95	2.8	134
162	MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. *Leukemia*, **2012**, 26, 778-87	10.7	109
161	Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. *Journal of Proteome Research*, **2011**, 10, 105-12	5.6	96
160	mTOR Cross-Talk in Cancer and Potential for Combination Therapy. *Cancers*, **2018**, 10,	6.6	78
159	A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. *Annals of Oncology*, **2015**, 26, 542-7	10.3	76
158	Role of mTOR Signaling in Tumor Microenvironment: An Overview. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	74
157	PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. *Advances in Biological Regulation*, **2014**, 56, 66-80	6.2	71

156	Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. *Annals of Oncology*, **2011**, 22, 2277-85	10.3	66
155	Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. *European Journal of Cancer*, **2013**, 49, 3609-15	7.5	64
154	Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. *Cell Death and Disease*, **2019**, 10, 201	9.8	61
153	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. *British Journal of Cancer*, **2014**, 110, 2165-9	8.7	56
152	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. *European Journal of Cancer*, **2013**, 49, 2134-42	7.5	55
151	PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?. *Cancers*, **2019**, 11,	6.6	53
150	Emerging MEK inhibitors. *Expert Opinion on Emerging Drugs*, **2010**, 15, 203-23	3.7	50
149	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. *Annals of Surgical Oncology*, **2015**, 22, 2094-100	3.1	48
148	Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. *European Urology*, **2010**, 58, 906-11	10.2	48
147	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. *World Journal of Gastroenterology*, **2015**, 21, 4788-801	5.6	48
146	PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. *Cancers*, **2019**, 11,	6.6	47
145	Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. *Molecular Cancer*, **2014**, 13, 230	42.1	47
144	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. *Journal of Molecular Medicine*, **2012**, 90, 667-79	5.5	46
143	Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. *Cell Discovery*, **2017**, 3, 17022	22.3	44
142	Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. *Oncotarget*, **2015**, 6, 12783-95	3.3	44
141	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. *Journal of Urology*, **2015**, 193, 41-7	2.5	43
140	Emerging pathways and future targets for the molecular therapy of pancreatic cancer. *Expert Opinion on Therapeutic Targets*, **2011**, 15, 1183-96	6.4	42
139	Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. *Current Pharmaceutical Design*, **2014**, 20, 3944-57	3.3	42

138	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. *Journal of Experimental and Clinical Cancer Research*, **2010**, 29, 58	12.8	41
137	Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?. *Oncologist*, **2020**, 25, e555-e569	5.7	41
136	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. *Journal of Experimental and Clinical Cancer Research*, **2015**, 34, 156	12.8	40
135	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. *Scientific Reports*, **2017**, 7, 43013	4.9	36
134	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. *Oncotarget*, **2016**, 7, 11332-48	3.3	36
133	Imatinib mesylate in thymic epithelial malignancies. *Cancer Chemotherapy and Pharmacology*, **2012**, 69, 309-15	3.5	35
132	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. *Journal of Hematology and Oncology*, **2013**, 6, 67	22.4	35
131	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. *Journal of Molecular Medicine*, **2012**, 90, 1133-44	5.5	34
130	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. *Targeted Oncology*, **2015**, 10, 517-22	5	32
129	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. *Carcinogenesis*, **2018**, 39, 971-980	4.6	32
128	Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. *Cell Death and Disease*, **2015**, 6, e1850	9.8	31
127	Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. *Scientific Reports*, **2017**, 7, 13024	4.9	30
126	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. *Oncotarget*, **2015**, 6, 32089-103	3.3	30
125	Molecular Tumor Boards in Clinical Practice. *Trends in Cancer*, **2020**, 6, 738-744	12.5	29
124	Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. *Clinical Lung Cancer*, **2014**, 15, 411-417.e4	4.9	28
123	Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. *Journal of Experimental and Clinical Cancer Research*, **2011**, 30, 54	12.8	28
122	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. *Cancers*, **2020**, 12,	6.6	28
121	Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. *Cancers*, **2020**, 12,	6.6	26

120	Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. *Clinical Cancer Research*, **2012**, 18, 3316-27	12.9	26
119	EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. *Journal of Thoracic Oncology*, **2012**, 7, 672-80	8.9	26
118	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. *Cancers*, **2019**, 11,	6.6	25
117	Biology of metastatic renal cell carcinoma. *Journal of Cancer*, **2011**, 2, 369-73	4.5	25
116	Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. *Oncology*, **2010**, 78, 141-9	3.6	25
115	Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. *Journal of Experimental and Clinical Cancer Research*, **2011**, 30, 115	12.8	23
114	Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. *Oncotarget*, **2014**, 5, 11054-63	3.3	23
113	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. *Journal of Experimental and Clinical Cancer Research*, **2018**, 37, 140	12.8	22
112	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. *Clinical Genitourinary Cancer*, **2018**, 16, e945-e951	3.3	22
111	Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. *Future Oncology*, **2014**, 10, 2141-7	3.6	21
110	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. *Cell Cycle*, **2012**, 11, 4447-61	4.7	21
109	Molecular and genetic bases of pancreatic cancer. *Current Drug Targets*, **2012**, 13, 731-43	3	21
108	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. *Mediators of Inflammation*, **2019**, 2019, 7652014	4.3	21
107	Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. *International Journal of Cancer*, **2013**, 133, 1016-22	7.5	20
106	Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. *Clinical Genitourinary Cancer*, **2013**, 11, 471-6	3.3	19
105	Maintenance therapy in NSCLC: why? To whom? Which agent?. *Journal of Experimental and Clinical Cancer Research*, **2011**, 30, 50	12.8	19
104	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. *Cancers*, **2019**, 11,	6.6	18
103	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. *Cancer Immunology, Immunotherapy*, **2019**, 68, 609-618	7.4	18

102	Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. *Pathology*, **2020**, 52, 297-309	1.6	18
101	KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. *Journal of Experimental and Clinical Cancer Research*, **2020**, 39, 227	12.8	18
100	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. *Clinical Genitourinary Cancer*, **2019**, 17, e903-e908	3.3	16
99	Exercise Levels and Preferences in Cancer Patients: A Cross-Sectional Study. *International Journal of Environmental Research and Public Health*, **2020**, 17,	4.6	16
98	Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. *Scientific Reports*, **2019**, 9, 12286	4.9	15
97	Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. *Journal of Experimental and Clinical Cancer Research*, **2013**, 32, 91	12.8	15
96	Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. *BMC Cancer*, **2010**, 10, 675	4.8	15
95	Targeting targeted agents: open issues for clinical trial design. *Journal of Experimental and Clinical Cancer Research*, **2009**, 28, 66	12.8	15
94	Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer. *Current Medicinal Chemistry*, **2017**, 24, 1383-1402	4.3	15
93	The pattern of hMENA isoforms is regulated by TGF-β in pancreatic cancer and may predict patient outcome. *OncoImmunology*, **2016**, 5, e1221556	7.2	15
92	From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. *Cells*, **2020**, 9,	7.9	14
91	Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?. *Journal of Viral Hepatitis*, **2012**, 19 Suppl 1, 52-9	3.4	14
90	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. *Cancers*, **2019**, 12,	6.6	14
89	Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. *Journal of Experimental and Clinical Cancer Research*, **2018**, 37, 278	12.8	14
88	Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. *Journal of Thoracic Oncology*, **2015**, 10, 1341-1348	8.9	13
87	Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. *Expert Review of Anticancer Therapy*, **2013**, 13, 697-709	3.5	12
86	Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. *Expert Review of Anticancer Therapy*, **2012**, 12, 1545-57	3.5	12
85	First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. *World Journal of Gastroenterology*, **2013**, 19, 4511-9	5.6	12

84	PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	12
83	Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer. *Journal of Oncology*, **2019**, 2019, 5373580	4.5	11
82	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. *Critical Reviews in Oncology/Hematology*, **2015**, 93, 50-9	7	11
81	Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	11
80	Targeting KRAS: The Elephant in the Room of Epithelial Cancers. *Frontiers in Oncology*, **2021**, 11, 638360	5.3	11
79	Muscle derangement and alteration of the nutritional machinery in NSCLC. *Critical Reviews in Oncology/Hematology*, **2019**, 141, 43-53	7	10
78	Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. *Annals of Surgical Oncology*, **2020**, 27, 5325-5334	3.1	10
77	Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'. *Current Pharmaceutical Design*, **2014**, 20, 3958-72	3.3	10
76	Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg. *Thrombosis Research*, **2020**, 194, 216-219	8.2	10
75	Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. *Expert Review of Molecular Diagnostics*, **2020**, 20, 169-185	3.8	10
74	Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic. *European Journal of Cancer*, **2020**, 135, 159-169	7.5	9
73	Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). *Cancers*, **2020**, 12,	6.6	9
72	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2018**, 18, 435-446	2.2	9
71	Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. *Journal of Thoracic Oncology*, **2018**, 13, 568-575	8.9	9
70	Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer. *Annals of Oncology*, **2017**, 28, 2896-2898	10.3	9
69	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. *Future Oncology*, **2015**, 11, 3159-66	3.6	9
68	Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. *Journal of Urology*, **2015**, 193, 1905-10	2.5	9
67	A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. *Pharmacogenomics*, **2014**, 15, 609-18	2.6	9

66	Renal cancer: new models and approach for personalizing therapy. *Journal of Experimental and Clinical Cancer Research*, **2018**, 37, 217	12.8	9
65	The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?. *PLoS ONE*, **2015**, 10, e0120427	3.7	8
64	Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different Germline Mutations: New Horizons from Tumor Molecular Profiling. *Genes*, **2021**, 12,	4.2	8
63	Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 109-14	3.5	8
62	Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. *Clinical Oncology*, **2021**, 33, e31-e38	2.8	8
61	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. *Critical Reviews in Oncology/Hematology*, **2016**, 106, 132-42	7	7
60	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. *Canadian Urological Association Journal*, **2014**, 8, E121-5	1.2	7
59	Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. *Cell Death and Disease*, **2012**, 3, e440	9.8	7
58	Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. *Oncotarget*, **2017**, 8, 108463-108479	3.3	7
57	Infections and Immunotherapy in Lung Cancer: A Bad Relationship?. *International Journal of Molecular Sciences*, **2020**, 22,	6.3	7
56	Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report. *Clinical Lung Cancer*, **2019**, 20, e514-e516	4.9	6
55	Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma. *Journal of the European Academy of Dermatology and Venereology*, **2016**, 30, 1507-11	4.6	6
54	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. *Expert Opinion on Drug Discovery*, **2013**, 8, 1381-97	6.2	6
53	PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 597-608	4	6
52	Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. *Digestive and Liver Disease*, **2011**, 43, 225-30	3.3	6
51	An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?. *Anti-Cancer Drugs*, **2010**, 21, 459-64	2.4	6
50	An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. *Expert Opinion on Investigational Drugs*, **2015**, 24, 1143-61	5.9	5
49	Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. *Cancers*, **2020**, 12,	6.6	5

48	"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients. *PLoS ONE*, **2020**, 15, e0227846	3.7	5
47	Early recurrence risk: aromatase inhibitors versus tamoxifen. *Expert Review of Anticancer Therapy*, **2010**, 10, 1239-53	3.5	5
46	OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). *Journal of Thoracic Oncology*, **2017**, 12, S266-S267	8.9	4
45	Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome. *ESMO Open*, **2020**, 5, e000689	6	4
44	High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. *Frontiers in Oncology*, **2020**, 10, 588862	5.3	4
43	Physical Activity for Oncological Patients in COVID-19 Era: No Time to Relax. *JNCI Cancer Spectrum*, **2020**, 4, pkaa071	4.6	4
42	A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920947969	5.4	4
41	Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar. *Frontiers in Oncology*, **2020**, 10, 600940	5.3	4
40	Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. *Frontiers in Oncology*, **2021**, 11, 650293	5.3	4
39	A multimodal approach to cancer-related cachexia: from theory to practice. *Expert Review of Anticancer Therapy*, **2021**, 21, 819-826	3.5	4
38	Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19. *Infectious Diseases and Therapy*, **2021**, 10, 1579-1590	6.2	4
37	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. *Cancer Immunology, Immunotherapy*, **2021**, 70, 1583-1592	7.4	4
36	Optimizing clinical benefit with targeted treatment in mRCC: "Tumor growth rate" as an alternative clinical endpoint. *Critical Reviews in Oncology/Hematology*, **2016**, 102, 73-81	7	3
35	Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report. *Future Science OA*, **2020**, 7, FSO659	2.7	3
34	Exercise prehabilitation in lung cancer: Getting stronger to recover faster. *European Journal of Surgical Oncology*, **2021**, 47, 1847-1855	3.6	3
33	Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients. *Pancreatology*, **2021**,	3.8	3
32	Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives. *Expert Review of Anticancer Therapy*, **2020**, 20, 531-542	3.5	2
31	Second-line chemotherapy in advanced biliary cancer: the present now will later be past. *Annals of Oncology*, **2014**, 25, 2443-2444	10.3	2

30	Evolving pancreatic cancer treatment: From diagnosis to healthcare management.. *Critical Reviews in Oncology/Hematology*, **2021**, 169, 103571	7	2
29	ICGC-ARGO precision medicine: familial matters in pancreatic cancer.. *Lancet Oncology, The*, **2022**, 23, 25-26	21.7	2
28	Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.. *ESMO Open*, **2021**, 7, 100308	6	2
27	Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors. *Frontiers in Immunology*, **2021**, 12, 672219	8.4	2
26	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. *Clinical Lung Cancer*, **2021**, 22, 351-360	4.9	2
25	Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report. *Immunotherapy*, **2021**, 13, 971-976	3.8	2
24	Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus -paclitaxel for Advanced Pancreatic Adenocarcinoma. *Frontiers in Oncology*, **2021**, 11, 688889	5.3	2
23	Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. *World Journal of Gastrointestinal Surgery*, **2021**, 13, 885-903	2.4	2
22	ASO Author Reflections: Preoperative Nutritional Care: The 'Cinderella' of Surgical Management in Patients with Pancreatic Cancer. *Annals of Surgical Oncology*, **2020**, 27, 5335-5336	3.1	1
21	Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. *Lung Cancer*, **2019**, 134, 121-126	5.9	1
20	Lost in translation: bridging the gap between cancer research and effective therapies. *Cell Death and Differentiation*, **2011**, 18, 1082-4	12.7	1
19	Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Clinical implications.. *Journal of Clinical Oncology*, **2020**, 38, e16769-e16769	2.2	1
18	BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer. *Communications Biology*, **2020**, 3, 546	6.7	1
17	Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. *Frontiers in Oncology*, **2021**, 11, 662205	5.3	1
16	Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface. *ESMO Open*, **2021**, 6, 100028	6	1
15	Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study. *Breast*, **2021**, 60, 6-14	3.6	1
14	Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy?. *Nutrition*, **2022**, 98, 111637	4.8	1
13	SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 148	12.8	1

12	Exercise oncology: It is time to make a change.. *Patient Education and Counseling*, **2022**,	3.1	0
11	Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research. *European Journal of Oncology Nursing*, **2021**, 55, 102061	2.8	0
10	A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma. *BMC Cancer*, **2021**, 21, 165	4.8	0
9	Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability. *Journal of Cancer Education*, **2021**, 1	1.8	0
8	Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona.. *Annals of Oncology*, **2022**,	10.3	0
7	Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy?. *Acta Oncologica*, **2021**, 1-5	3.2	0
6	Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer. *Expert Review of Anticancer Therapy*,1-11	3.5	0
5	Effect of evidence-based nutrition educational intervention on adherence to dietary guidelines (ADG) and weight management among early-stage breast cancer (EBC) patients (pts): A prospective trial.. *Journal of Clinical Oncology*, **2020**, 38, 12056-12056	2.2	
4	Running with cancer: A qualitative study to evaluate barriers and motivations in running for female oncological patients **2020**, 15, e0227846		
3	Running with cancer: A qualitative study to evaluate barriers and motivations in running for female oncological patients **2020**, 15, e0227846		
2	Running with cancer: A qualitative study to evaluate barriers and motivations in running for female oncological patients **2020**, 15, e0227846		
1	Running with cancer: A qualitative study to evaluate barriers and motivations in running for female oncological patients **2020**, 15, e0227846		